<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:chebi fb="0" ids="31690">Imatinib mesylate</z:chebi> specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of <z:e sem="disease" ids="C0238198" disease_type="Neoplastic Process" abbrv="GIST|GANT">gastrointestinal stromal tumours</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Because other KIT-expressing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> might benefit from <z:chebi fb="0" ids="45783">Imatinib</z:chebi> therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND RESULTS: Tissue microarrays (<z:chebi fb="39" ids="18139,53050">TMAs</z:chebi>) containing 824 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and 342 Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) cases were immunohistochemically analysed for the expression of the KIT protein </plain></SENT>
<SENT sid="3" pm="."><plain>Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis </plain></SENT>
<SENT sid="4" pm="."><plain>One T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the 747 NHL cases (0.3%) were positive for KIT </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e> were Kit-negative </plain></SENT>
<SENT sid="6" pm="."><plain>None of the KIT-positive cases showed a kit gene mutation </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: KIT expression is a very rare event in NHL and virtually absent in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with <z:chebi fb="0" ids="45783">Imatinib</z:chebi> may be ineffective </plain></SENT>
</text></document>